ADC Therapeutics SA - ADCT STOCK NEWS

ADC Therapeutics (NYSE: ADCT) has published results from the LOTIS-2 trial in The Lancet Oncology, demonstrating the efficacy of ZYNLONTA™ for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL). In this Phase 2 trial involving 145 patients, ZYNLONTA showed a 48.3% overall response rate, with a complete response rate of 24.1%. The median duration of response was 10.3 months. Despite some adverse events like neutropenia (25.5%), the study reinforces ZYNLONTA's potential as a standard treatment for DLBCL patients in need of new options, following FDA approval.

ADC Therapeutics (NYSE: ADCT) reported Q1 2021 results, highlighted by the accelerated FDA approval of ZYNLONTA for treating relapsed or refractory DLBCL. This approval broadens treatment options for patients with difficult-to-treat cancers. Cash equivalents stood at $383.1 million, down from $439.2 million at year-end 2020. R&D expenses increased to $39.2 million, reflecting investments for ZYNLONTA's potential. Net loss was $51.5 million or $0.67 per share, up from $43.5 million in Q1 2020, driven by organizational expansion and preparation for ZYNLONTA's launch.

ADC Therapeutics (NYSE: ADCT) announced the inclusion of ZYNLONTA™ (loncastuximab tesirine-lpyl) in the NCCN Guidelines as a category 2A treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This follows the recent accelerated FDA approval for adult patients after two or more systemic therapy lines. ZYNLONTA is noted for addressing significant unmet medical needs among patients with challenging disease profiles.

ADC Therapeutics (NYSE: ADCT) announced its CEO, Chris Martin, will participate in two virtual investor conferences in May 2021. The details include the BofA Securities Virtual Health Care Conference on May 11 at 8:00 a.m. ET and the RBC Capital Markets Global Healthcare Conference on May 19 at 9:45 a.m. ET. Live webcasts of the discussions will be available on their website, with replays accessible for 30 days. ADC focuses on developing innovative antibody drug conjugates for cancer treatment.

ADC Therapeutics (NYSE: ADCT) has announced a conference call on May 6, 2021, at 8:30 a.m. EDT to discuss its first quarter financial results and business updates. The call can be accessed via phone or through a live webcast on the company’s investor website. ADC Therapeutics is focused on developing antibody drug conjugates (ADCs) aimed at treating various cancers, including its FDA-approved ADC ZYNLONTA for lymphoma. The company also has ongoing clinical trials for other ADCs targeting hematological malignancies and solid tumors.

ADC Therapeutics SA (NYSE: ADCT) announced FDA approval for ZYNLONTA™ (loncastuximab tesirine-lpyl) to treat adult patients with relapsed or refractory large B-cell lymphoma after multiple therapies. This accelerated approval is based on a 48.3% overall response rate from the pivotal LOTIS-2 trial. The trial included 145 patients, revealing a complete response rate of 24.1%. ZYNLONTA's commercial launch in the U.S. is imminent, alongside an Advancing Patient Support Program for eligible patients. However, continued approval is dependent on further clinical benefit verification.

Overland ADCT BioPharma has appointed Eric Koo as Chief Executive Officer. With over 25 years in the pharmaceutical industry, Koo aims to enhance drug approvals and launches in Asia. His past leadership roles include Vice President at Takeda China and Director at Merck. Koo will lead the development of innovative cancer medicines, particularly the ADC Lonca, with the U.S. PDUFA date approaching in May. Overland ADCT is focused on expanding access to antibody drug conjugates for challenging hematologic and solid tumors in greater China and Singapore.

ADC Therapeutics (NYSE: ADCT) reported financial results for Q4 and FY 2020, highlighting a cash balance of $439.2 million. The company is preparing for the launch of its lead candidate, Lonca, with a PDUFA date set for May 21, 2021. R&D expenses increased to $48.6 million in Q4 and $142 million for the year. The pivotal Phase 2 trial of Camidanlumab Tesirine (Cami) is complete, showing promising results in treating Hodgkin lymphoma. Significant net losses were reported at $55.9 million for Q4 and $246.3 million for the year, reflecting higher operational costs.

ADC Therapeutics (NYSE: ADCT), a biotechnology firm focused on targeted antibody drug conjugates, will host a conference call on March 18, 2021, at 8:30 a.m. ET to discuss its financial results for Q4 and year-end 2020, along with business updates. The lead candidate, loncastuximab tesirine (Lonca), for relapsed large B-cell lymphoma has received priority review by the FDA with a PDUFA date of May 21, 2021. A second candidate, camidanlumab tesirine (Cami), is in a pivotal Phase 2 trial for Hodgkin lymphoma.